Skip Navigation

European Heart Journal 2001 22(17):1527-1560; doi:10.1053/euhj.2001.2783
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Swedberg, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swedberg, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Task Force Report

Guidelines for the diagnosis and treatment of chronic heart failure

Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology, W. J. Remme, Co-Chairmanf1 and K. Swedberg, Co-Chairman

Received May 1, 2001; accepted May 2, 2001

f1 Correspondence: Professor Willem J. Remme, Sticares Cardiovascular Research Foundation, "Oeverstate", Oever 7, P.O. Box 882, 3160 AB, Rhoon, The Netherlands. Professor Karl Swedberg, Göteborg University, Department of Medicine, Sahlgrenska University Hospital, SE-416 85 Göteborg, Sweden.

References

  1. Eur Heart J. 1995;16:741–751[Free Full Text]
  2. Eur Heart J. 1997;18:736–753[Free Full Text]
  3. Cowie MR, Struthers AD, Wood DA. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349–1353[CrossRef][ISI][Medline]
  4. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441–1446[ISI][Medline]
  5. McMurray J, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalization for heart failure in Scotland 1980–1990. Eur Heart J. 1993;14:1158–1162[Abstract/Free Full Text]
  6. Murdoch DR, Love MP, Robb SD. Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979–1992. Eur Heart J. 1998;19:1929–1935
  7. Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail. 1999;1:229–241[CrossRef][ISI][Medline]
  8. Mosterd A, Hoes AW, de Bruyne MC. Prevalence of heart failure and left ventricular dysfunction in the general population. Eur Heart J. 1999;20:447–455[Abstract/Free Full Text]
  9. McDonagh TA, Morrison CE, Lawrence A. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829–P833[CrossRef][ISI][Medline]
  10. Cowie MR, Wood DA, Coats AJ. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000;83:505–510[Abstract/Free Full Text]
  11. Senni M, Tribouilloy CM, Rodeheffer RJ. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med. 1999;159:29–34[Abstract/Free Full Text]
  12. N Engl J Med. 1992;327:685–691[Abstract]
  13. MacIntyre K, Capewell S, Stewart S. Evidence of improving prognosis in heart failure: trends in case fatality in 66547 patients hospitalized between 1986 and 1995. Circulation. 2000;102:1126–1131[Abstract/Free Full Text]
  14. Wheeldon NM, MacDonald TM, Flucker CJ, McKendrick AD, McDevitt DG, Struthers AD. Echocardiography in chronic heart failure in the community. Q J Med. 1993;86:17–23[ISI][Medline]
  15. Remes W, Lansimies E, Pyorala K. Usefulness of M-Mode echocardiography. Cardiology. 1991;78:267–277[ISI][Medline]
  16. Wood P. Heart Failure. Wood P. Diseases of the Heart and Circulation. London: Eyre and Spottiswoode; 1950.
  17. Braunwald E. Heart failure: An overview. Fishma AP. Heart Failure. New York: McGraw-Hill; 1977.
  18. Denolin H, Kuhn H, Krayenbuehl HP, Loogen F, Reale A. The definition of heart failure. Eur Heart J. 1983;4:445–446[Free Full Text]
  19. Poole-Wilson PA. Chronic heart failure causes pathophysiology, prognosis, clinical manifestations, investigation. Julian DG, Camm AJ, Fox KM, Hall RJC, Poole-Wilson P. Diseases of the Heart. London: Bailliere-Tindall; 1989.
  20. Sutton GC. Epidemiologic aspects of heart failure. Am Heart J. 1990;120:1538–1540[CrossRef][ISI][Medline]
  21. Choudhri AH, Cleland JG, Rowlands PC, Tran TL, McCarty M, al-Kutoubi MA. Unsuspected renal artery stenosis in peripheral vascular disease. BMJ. 1990;301:1197–1198[ISI][Medline]
  22. Lipkin DP, Canepa-Anson R, Stephens MR, Poole-Wilson PA. Factors determining symptoms in heart failure: comparison of fast and slow exercise tests. Br Heart J. 1986;55:439–445[Abstract/Free Full Text]
  23. Puri S, Baker BL, Oakley CM, Hughes JM, Cleland JG. Increased alveolar/capillary membrane resistance to gas transfer in patients with chronic heart failure. Br Heart J. 1994;72:140–144[Abstract/Free Full Text]
  24. Poole-Wilson PA. Relation of pathophysiologic mechanisms to outcome in heart failure. J Am Coll Cardiol. 1993;22:22A–9A[Medline]
  25. Coats AJ, Adamopoulos S, Meyer TE, Conway J, Sleight P. Effects of physical training in chronic heart failure. Lancet. 1990;335:63–66[CrossRef][ISI][Medline]
  26. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. BMJ. 2000;321:215–218[Abstract/Free Full Text]
  27. Wilson JR, Mancini DM, Dunkman WB. Exertional fatigue due to skeletal muscle dysfunction in patients with heart failure. Circulation. 1993;87:470–475[Abstract/Free Full Text]
  28. Cleland JG, Oakley CM. Vascular tone in heart failure: the neuroendocrine-therapeutic interface. Br Heart J. 1991;66:264–267[Free Full Text]
  29. Francis GS, Benedict C, Johnstone DE. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation. 1990;82:1724–1729[Abstract/Free Full Text]
  30. Swedberg K. Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. Review. Eur J Heart Fail. 2000;2:229–233[CrossRef][ISI][Medline]
  31. Mancia G, Seravalle G, Giannattasio C. Reflex cardiovascular control in congestive heart failure. Am J Cardiol. 1992;69:17G–22G[Medline]
  32. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol. 1993;71:3
  33. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Review. Chest. 1994;105:897–904[Free Full Text]
  34. Gadsboll N, Hoilund-Carlsen PF, Nielsen CG. Symptoms and signs of heart failure in patients with myocardial infarction: reproducibility and relationship to chest X-ray, radionuclide ventriculography and right heart catherization. Eur Heart J. 1989;10:1017–1028[Abstract/Free Full Text]
  35. Marantz PR, Tobin JN, Wassertheil-Smoller S. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation. 1988;77:607–612[Abstract/Free Full Text]
  36. Butman SM, Ewy GA, Standen JR, Kern KB, Hahn E. Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. J Am Coll Cardiol. 1993;22:968–974[Abstract]
  37. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;10:884–888
  38. Folland ED, Kriegel BJ, Henderson WG, Hammermeister KE, Sethi GK. Implications of third heart sounds in patients with valvular heart disease. The Veterans Affairs Cooperative Study on Valvular Heart Disease. N Engl J Med. 1992;327:458–462[Abstract]
  39. Ishmail A, Wing S, Ferguson J, Hutchinson T, Magder S, Flegel J. Interobserver agreement by ausculation in the presence of a third heart sound in patients with congestive heart failure. Chest. 1987;91:870–873[Abstract/Free Full Text]
  40. Spiteri MA, Cook DG, Clarke SW. Reliability of eliciting physical signs in examination of the chest. Lancet. 1988;1:873–875[CrossRef][ISI][Medline]
  41. van den Broek SA, van Veldhuisen DJ, de Graeff PA, Landsman ML, Hillege H, Lie KI. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;70:359–363[CrossRef][ISI][Medline]
  42. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20:457–464[CrossRef][ISI][Medline]
  43. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992;124:1017–1025[CrossRef][ISI][Medline]
  44. Rihal CS, Davis KB, Kennedy JW, Gersh BJ. The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. Am J Cardiol. 1995;75:220–223[CrossRef][ISI][Medline]
  45. Gillespie ND, McNeill G, Pringle T, Ogston S, Struthers AD, Pringle SD. Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea. BMJ. 1997;314:936–940[Abstract/Free Full Text]
  46. Mosterd A, de Bruijne MC, Hoes AW, Deckers JW, Hofman A, Grobbee DE. Usefulness of echocardiography in detecting left ventricular dysfunction in population-based studies (The Rotterdam Study). Am J Cardiol. 1997;79:103–104[CrossRef][ISI][Medline]
  47. Badgett RG, Lucey CR, Mulrow CD. Can the clinical examination diagnose left-sided heart failure in adults? JAMA. 1997;277:1712–1719[Abstract/Free Full Text]
  48. Alam M, Rosenhamer G, Hoglund C. Comparability of echocardiography and chest X-ray following myocardial infarction. J Intern Med. 1989;226:171–175[ISI][Medline]
  49. Kono T, Suwa M, Hanada H, Hirota Y, Kawamura K. Clinical significance of normal cardiac silhouette in dilated cardiomyopathy–evaluation based upon echocardiography and magnetic resonance imaging. Jpn Circ J. 1992;56:359–365[Medline]
  50. Madsen EB, Gilpin E, Slutsky RA, Ahnve S, Henning H, Ross J Jr. Usefulness of the chest x-ray for predicting abnormal left ventricular function after acute myocardial infarction. Am Heart J. 1984;108:1431–1436[CrossRef][ISI][Medline]
  51. McNamara RF, Carleen E, Moss AJ. Estimating left ventricular ejection fraction after myocardial infarction by various clinical parameters. Am J Cardiol. 1988;62:192–196[CrossRef][ISI][Medline]
  52. Badgett RG, Mulrow CD, Otto PM, Ramirez G. How well can the chest radiograph diagnose left ventricular dysfunction? J Gen Intern Med. 1996;11:625–634[ISI][Medline]
  53. Miniati M, Pistolesi M, Paoletti P. Objective radiographic criteria to differentiate cardiac, renal, and injury lung edema. Invest Radiol. 1988;23:433–440[CrossRef][ISI][Medline]
  54. Kostuk W, Barr JW, Simon AL, Ross J Jr. Correlations between the chest film and hemodynamics in acute myocardial infarction. Circulation. 1973;48:624–632[Abstract/Free Full Text]
  55. Chakko S, Woska D, Martinez H. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med. 1991;90:353–359[ISI][Medline]
  56. Kundel HL, Revesz G. Digital analysis of chest radiographs in pulmonary vascular congestion. Radiology. 1982;143:407–410[Abstract/Free Full Text]
  57. Grover MSRA, Higgins CB, Shabetai R. Extravascular lung water in patients with congestive heart failure. Radiology. 1983;147:659–662[Abstract/Free Full Text]
  58. Otterstad JE, Froeland G, St John Sutton M, Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J. 1997;18:507–513[Abstract/Free Full Text]
  59. Hoglund C, Alam M, Thorstrand C. Atrioventricular valve plane displacement in healthy persons. An echocardiographic study. Acta Med Scand. 1988;224:557–562[ISI][Medline]
  60. Tei C, Ling TH, Hodge DO. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function–a study in normals and dilated cardiomyopathy. J Cardiol. 1995;26:357–366[Medline]
  61. Berning J, Steensgaard-Hansen F. Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. Am J Cardiol. 1990;65:567–576[CrossRef][ISI][Medline]
  62. Willenheimer RB, Israelsson BA, Cline CM, Erhardt LR. Simplified echocardiography in the diagnosis of heart failure. Scand Cardiovasc J. 1997;31:9–16[ISI][Medline]
  63. Eur Heart J. 1998;19:990–1003[Free Full Text]
  64. Stefanadis C, Dernellis J, Toutouzas P. A clinical appraisal of left atrial function. Eur Heart J. 2001;22:22–36[Free Full Text]
  65. Pierard LA, Lancellotti P, Benoit T. Myocardial viability. Stress echocardiography vs nuclear medicine. Eur Heart J. 1997;18:D117–23
  66. Williams MJ, Odabashian J, Lauer MS, Thomas JD, Marwick TH. Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction. J Am Coll Cardiol. 1996;27:132–139[Abstract]
  67. Pasquet A, Robert A, D'Hondt AM, Dion R, Melin JA, Vanoverschelde JL. Prognostic value of myocardial ischemia and viability in patients with chronic left ventricular ischemic dysfunction. Circulation. 1999;100:141–148[Abstract/Free Full Text]
  68. Udelson JE, Bonow RO. Radionuclide angiographic evaluation of left ventricular diastolic function. Gaasch WH, LeWinter M. Left ventricular diastolic dysfunction and heart failure. Malvern: Lea & Febiger; 1994. p. 167–191
  69. Kramer CM. Integrated approach to ischemic heart disease. Reichek N. Cardiology Clinics. London: W.B. Saunders Company; 1998. p. 267–276
  70. Cook DG, Shaper AG. Breathlessness, lung function and the risk of heart attack. Eur Heart J. 1988;9:1215–1222[Abstract/Free Full Text]
  71. Kannel WB, D'Agostino RB, Silbershatz H. Use of vital capacity for cardiac failure risk estimation in persons with coronary disease and left ventricular hypertrophy. Am J Cardiol. 1996;77:1155–1158[CrossRef][ISI][Medline]
  72. McNamara RM, Cionni DJ. Utility of the peak expiratory flow rate in the differentiation of acute dyspnea. Cardiac vs. pulmonary origin. Chest. 1992;101:129–132[Abstract/Free Full Text]
  73. Diamopoulon I, Tsintzas OK, Daganou M, Cokkinos D, Tzelepis GE. Contribution of lung function to exercise capacity in patients with chronic heart failure. Respiration. 1999;66:144–149[CrossRef][ISI][Medline]
  74. Mamas S, Nanas J, Kassiotis C. Respiratory muscle performance is related to oxygen kinetics during maximal exercise and early recovery in patients with congestive heart failure. Circulation. 1999;100:503–508[Abstract/Free Full Text]
  75. Eur Heart J. 2001;22:37–45[Free Full Text]
  76. Guyatt GH, Sullivan MJ, Thompson PJ. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. CMAJ. 1985;132:919–923[Abstract]
  77. Bittner V, Weiner DH, Yusuf S. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA. 1993;270:1702–1707[Abstract]
  78. McDonagh TA, Robb SD, Murdoch DR. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9–13[CrossRef][ISI][Medline]
  79. Lerman A, Gibbons RJ, Rodeheffer RJ. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet. 1993;341:1105–1109[CrossRef][ISI][Medline]
  80. Tsutamoto T, Wada A, Maeda K. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J. 1999;20:1799–1807[Abstract/Free Full Text]
  81. Hall C, Rouleau JL, Moye L. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994;89:1934–1942[Abstract/Free Full Text]
  82. McDonagh TA, Cunningham AD, Morrison CD. Left ventricular dysfunction, natriuretic peptides and mortality in an urban population. Heart. 2001;:
  83. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–1130[CrossRef][ISI][Medline]
  84. Dutka DP, Olivotto I, Ward S. Plasma neuro-endocrine activity in very elderly subjects and patients with and without heart failure. Eur Heart J. 1995;16:1223–1230[Abstract/Free Full Text]
  85. Doval HC, Nul DR, Grancelli HO. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. Circulation. 1996;94:3198–3203[Abstract/Free Full Text]
  86. Teerlink JR, Jalaluddin M, Anderson S. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. Circulation. 2000;101:40–46[Abstract/Free Full Text]
  87. Nolan J, Flapan AD, Capewell S, MacDonald TM, Neilson JM, Ewing DJ. Decreased cardiac parasympathetic activity in chronic heart failure and its relation to left ventricular function. Br Heart J. 1992;67:482–485[Abstract/Free Full Text]
  88. Malik M, Camm AJ. Heart rate variability: from facts to fancies. J Am Coll Cardiol. 1993;22:566–568[Medline]
  89. Hohnloser SH, Klingenheben T, Zabel M, Schroder F, Just H. Intraindividual reproducibility of heart rate variability. PACE. 1992;15:2211–2214
  90. Mortara A, La Rovere MT, Signorini MG. Can power spectral analysis of heart rate variability identify a high risk subgroup of congestive heart failure patients with excessive sympathetic activation? A pilot study before and after heart transplantation. Br Heart J. 1994;71:422–430[Abstract/Free Full Text]
  91. Panina G, Khot UN, Nunziata E, Cody RJ, Binkley PF. Role of spectral measures of heart rate variability as markers of disease progression in patients with chronic congestive heart failure not treated with angiotensin-converting enzyme inhibitors. Am Heart J. 1996;131:153–157[CrossRef][ISI][Medline]
  92. Brouwer J, van Veldhuisen DJ, Man in't Veld AJ. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group. J Am Coll Cardiol. 1996;28:1183–1189[Abstract]
  93. Ponikowski P, Anker SD, Chua TP. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997;79:1645–1650[CrossRef][ISI][Medline]
  94. Good CB, McDermott L, McCloskey B. Diet and serum potassium in patients on ACE inhibitors. JAMA. 1995;274:538[CrossRef][ISI][Medline]
  95. Cooper HA, Exner DV, Domanski MJ. Light-to-moderate alcohol consumption and prognosis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:1753–1759[Abstract/Free Full Text]
  96. Anker SD, Chua TP, Ponikowski P. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526–534[Abstract/Free Full Text]
  97. Anker SD, Ponikowski P, Varney S. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–1053[CrossRef][ISI][Medline]
  98. DeBusk R, Drory Y, Goldstein I. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol. 2000;86:175–181[CrossRef][ISI][Medline]
  99. Feenstra J, Grobbee DE, Remme WJ, Stricker BH. Drug-induced heart failure. J Am Coll Cardiol. 1999;33:1152–1162[Abstract/Free Full Text]
  100. Eur Heart J. 2001;22:125–135[Free Full Text]
  101. Kober L, Torp-Pedersen C, Carlsen JE. Effects on mortality by trandolapril after myocardial infarction. N Engl J Med. 1995;333:1670–1676[Abstract/Free Full Text]
  102. Flather M, Yusuf S, Kober L. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575–1581[CrossRef][ISI][Medline]
  103. Lancet. 1993;342:821–828[ISI][Medline]
  104. Konstam MA, Rousseau MF, Kronenberg MW. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation. 1992;86:431–438[Abstract/Free Full Text]
  105. Greenberg B, Quinones MA, Koilpillai C. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91:2573–2581[Abstract/Free Full Text]
  106. Konstam MA, Patten RD, Thomas I. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J. 2000;139:1081–1087[CrossRef][ISI][Medline]
  107. Umemura K, Nakashima M, Saruta T. Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors. Life Sci. 1997;60:1583–1588[CrossRef][ISI][Medline]
  108. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70:479–487[CrossRef][ISI][Medline]
  109. Packer M, Poole-Wilson PA, Armstrong PW. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–2318[Abstract/Free Full Text]
  110. Kaddoura S, Patel D, Parameshwar J. Objective assessment of the response to treatment of severe heart failure using a 9-minute walk test on a patient-powered treadmill. J Card Fail. 1996;2:133–139[CrossRef][Medline]
  111. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17–22[Abstract/Free Full Text]
  112. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torasemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57:601–609[CrossRef][ISI][Medline]
  113. Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J. 1994;71:146–150[Abstract/Free Full Text]
  114. van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 1993;71:21A–8A[CrossRef][Medline]
  115. Edmonds CJ, Jasani B. Total-body potassium in hypertension patients during prolonged diuretic therapy. Lancet. 1972;2:8–12[CrossRef][Medline]
  116. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J. 1980;44:117–133[Abstract/Free Full Text]
  117. Anderson J, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RLBM. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1985;55:471–475[CrossRef][ISI][Medline]
  118. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985;72:536–546[Abstract/Free Full Text]
  119. Waagstein F, Bristow MR, Swedberg K. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441–1446[CrossRef][ISI][Medline]
  120. Circulation. 1994;90:1765–1773[Medline]
  121. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–1355[Abstract/Free Full Text]
  122. Colucci WS, Packer M, Bristow MR. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94:2800–2806[Abstract/Free Full Text]
  123. Bristow MR, Gilbert EM, Abraham WT. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807–2816[Abstract/Free Full Text]
  124. Lancet. 1997;349:375–380[CrossRef][ISI][Medline]
  125. Lancet. 1999;353:9–13[CrossRef][ISI][Medline]
  126. Lancet. 1999;353:2001–2007[CrossRef][ISI][Medline]
  127. Circulation. 2000;101:378–384[Medline]
  128. The Beta-blocker Evaluation of Survival Trial investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–1667[Abstract/Free Full Text]
  129. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 1997;29:1060–1066[Abstract]
  130. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546–551[Abstract/Free Full Text]
  131. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 1994;24:571–575[Abstract/Free Full Text]
  132. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30–34[Abstract/Free Full Text]
  133. Staessen J, Lijnen P, Fagard P, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457–465[Abstract]
  134. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and morality in patients with severe heart failure. N Engl J Med. 1999;341:709–717[Abstract/Free Full Text]
  135. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637–645[CrossRef][ISI][Medline]
  136. Pitt B, Segal R, Martinez FA. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–752[CrossRef][ISI][Medline]
  137. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587[CrossRef][ISI][Medline]
  138. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail. 1999;5:155–160[CrossRef][ISI][Medline]
  139. Khand AU, Rankin AC, Kaye GC, Cleland JG. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J. 2000;21:614–632[Abstract/Free Full Text]
  140. Khand AU, Rankin AC, Martin W, Taylor J, Cleland JGF. Digoxin or carvedilol for the treatment of atrial fibrillation in patients with heart failure? (Abstr). Heart. 2000;83:30[CrossRef]
  141. N Engl J Med. 1997;336:525–533[Abstract/Free Full Text]
  142. Cohn JN, Johnson G, Ziesche S. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310[Abstract]
  143. Cohn JN, Archibald DG, Phil M. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperation study. N Engl J Med. 1986;314:1547–1552[Abstract]
  144. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799–804[Abstract]
  145. Gogia H, Mehra A, Parikh S. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575–1580[Abstract]
  146. Cohn JN, Ziesche S, Smith R. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96:856–863[Abstract/Free Full Text]
  147. Thackray S, Witte K, Clark AL, Cleland JG. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail. 2000;2:209–212[CrossRef][ISI][Medline]
  148. Jones CG, Cleland JG. Meeting report–The LIDO, HOPE, MOXCON and WASH studies. Heart Outcomes Prevention Evaluation. The Warfarin/Aspirin Study of Heart Failure. Eur J Heart Fail. 1999;1:425–431[CrossRef][Medline]
  149. Gomes UC, Cleland JG. Heart failure update. Eur J Heart Fail. 1999;1:301–302[CrossRef][ISI][Medline]
  150. Hampton JR, van Veldhuisen DJ, Kleber FX. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet. 1997;349:971–977[CrossRef][ISI][Medline]
  151. Cleland JG, Cowburn PJ, Falk RH. Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. Eur Heart J. 1996;17:674–681[Free Full Text]
  152. Loh E, Sutton MS, Wun CC. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251–257[Abstract/Free Full Text]
  153. Cleland JG, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail. 1999;1:41–45[CrossRef][ISI][Medline]
  154. Ann Intern Med. 1992;116:1–5[ISI][Medline]
  155. Arch Intern Med. 1994;154:1449–1457[Abstract]
  156. Cleland JG. Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol. 1997;12:276–287[ISI][Medline]
  157. Samama MM, Cohen AT, Darmon JY. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793–800[Abstract/Free Full Text]
  158. Steinbeck G, Andresen D, Bach P. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med. 1992;327:987–992[Abstract]
  159. Levy S, Breithardt G, Campbell RW. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J. 1998;19:1294–1320[Abstract/Free Full Text]
  160. Singh SN, Fletcher RD, Fisher SG. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333:77–82[Abstract/Free Full Text]
  161. Torp-Pedersen C, Moller M, Bloch-Thomsen PE. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341:857–865[Abstract/Free Full Text]
  162. Haque WA, Boehmer J, Clemson BS, Leuenberger UA, Silber DH, Sinoway LI. Hemodynamic effects of supplemental oxygen administration in congestive heart failure. J Am Coll Cardiol. 1996;27:353–357[Abstract]
  163. Neff TA, Petty TL. Long-term continuous oxygen therapy in chronic airway obstruction. Mortality in relationship to cor pulmonale, hypoxia, and hypercapnia. Ann Intern Med. 1970;72:621–626[CrossRef][ISI][Medline]
  164. Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117:211–221[CrossRef][ISI][Medline]
  165. La Canna G, Alfieri O, Giubbini R, Gargano M, Ferrari R, Visioli O. Echocardiography during infusion of dobutamine for identification of reversibly dysfunction in patients with chronic coronary artery disease. J Am Coll Cardiol. 1994;23:617–626[Abstract]
  166. Argenziano M, Spotnitz HM, Whang W, Bigger JT, Parides M, Rose EA. Risk stratification for coronary bypass surgery in patients with left ventricular dysfunction. Analysis of the Coronary Artery Bypass Graft Patch Trial Database. Circulation. 1999;100:II-119–II-124
  167. Antunes PE, Ferrao de Oliveira J, Antunes MJ. Non-cardioplegic coronary surgery in patients with severe left ventricular dysfunction. Eur J Cardiothorac Surg. 1999;16:331–336[Abstract]
  168. Bolling SF, Deeb GM, Brunsting LA, Bach DS. Early outcome of mitral valve reconstruction in patients with end-stage cardiomyopathy. J Thorac Cardiovasc Surg. 1195;109:676–683
  169. Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg. 1998;115:381–386[Abstract/Free Full Text]
  170. McCarthy JF, McCarthy PM, Starling RC. Partial left ventriculectomy and mitral valve repair for end-stage congestive heart failure. Eur J Cardiothorac Surg. 1998;13:337–343
  171. Franco-Cereceda A, McCarthy PM, Blackstone EH. Partial left ventriculectomy for dilated cardiomyopathy: is this an alternative to transplantation? J Thorac Cardiovasc Surg. 2001;121:879–893[Abstract/Free Full Text]
  172. Alpert MA, Curtis JJ, Sanfelippo JF. Comparative survival after permanent ventricular and dual chamber pacing for patients with chronic high degree atrioventricular block with and without preexistent congestive heart failure. J Am Coll Cardiol. 1986;7:925–932[Abstract]
  173. Alpert MA, Curtis JJ, Sanfelippo JF. Comparative survival following permanent ventricular and dual-chamber pacing for patients with chronic symptomatic sinus node dysfunction with and without congestive heart failure. Am Heart J. 1987;113:958–965[CrossRef][ISI][Medline]
  174. Cazeau S, Ritter P, Lazarus A. Multisite pacing for end-stage heart failure: early experience. Pacing Clin Electrophysiol. 1996;19:1748–1757[CrossRef][Medline]
  175. Auricchio A, Stellbrink C, Block M. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation. 1999;99:2993–3001[Abstract/Free Full Text]
  176. Gras D, Mabo P, Tang T. Multisite pacing as a supplemental treatment of congestive heart failure: preliminary results of the Medtronic Inc. InSync Study. Pacing Clin Electrophysiol. 1998;21:2249–2255[CrossRef][Medline]
  177. Moss AJ, Hall WJ, Cannom DS. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940[Abstract/Free Full Text]
  178. N Engl J Med. 1997;337:1576–1583[Abstract/Free Full Text]
  179. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341:1882–1890[Abstract/Free Full Text]
  180. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report–1999. J Heart Lung Transplant. 1999;18:611–626[CrossRef][ISI][Medline]
  181. Paris W, Woodbury A, Thompson S. Returning to work after heart transplantation. J Heart Lung Transplant. 1993;12:46–53[ISI][Medline]
  182. Rimondini A, Cipolla CM, Della Bella P. Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med. 1987;83:43–48[ISI][Medline]
  183. Dormans TP, Huige RM, Gerlag PG. Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide. Heart. 1996;75:349–351[Abstract/Free Full Text]
  184. Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation. 1985;72:853–864[Abstract/Free Full Text]
  185. Opasich C, Febo O, Riccardi PG. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol. 1996;78:354–357[CrossRef][ISI][Medline]
  186. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190–1195[Abstract/Free Full Text]
  187. Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med. 1998;158:1067–1072[Abstract/Free Full Text]
  188. Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med. 1996;334:1441–1447[Abstract/Free Full Text]
  189. Ekman I, Andersson B, Ehnfors M, Matejka G, Persson B, Fagerberg B. Feasibility of a nurse-monitored, outpatient-care programme for elderly patients with moderate-to-severe, chronic heart failure. Eur Heart J. 1998;19:1254–1260[Abstract/Free Full Text]
  190. Jaarsma T, Halfens R, Huijer Abu-Saad H. Effects of education and support on self-care and resource utilization in patients with heart failure. Eur Heart J. 1999;20:673–682[Abstract/Free Full Text]
  191. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41[ISI][Medline]
  192. N Engl J Med. 1987;316:1429–1435[Abstract]
  193. N Engl J Med. 1991;325:293–302[Abstract]
  194. Pfeffer MA, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669–677[Abstract]
  195. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390[CrossRef][ISI][Medline]
  196. Packer M, Coats AJS, Fowler MB. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
Authors/Task Force Members, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, et al.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
Eur. Heart J., October 1, 2008; 29(19): 2388 - 2442.
[Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
M. J. Crespo, N. Cruz, P. I. Altieri, and N. Escobales
Enalapril and Losartan Are More Effective Than Carvedilol in Preventing Dilated Cardiomyopathy in the Syrian Cardiomyopathic Hamster
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2008; 13(3): 199 - 206.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
W. J. Remme, J. J.V. McMurray, F.D. R. Hobbs, A. Cohen-Solal, J. Lopez-Sendon, A. Boccanelli, F. Zannad, B. Rauch, K. Keukelaar, C. Macarie, et al.
Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians
Eur. Heart J., July 2, 2008; 29(14): 1739 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EchocardiogrHome page
E. Donal, M. Roulaud, P. Raud-Raynier, C. De Bisschop, C. Leclercq, G. Derumeaux, J.-C. Daubert, P. Mabo, and A. Denjean
Echocardiographic right ventricular strain analysis in chronic heart failure
Eur J Echocardiogr, December 1, 2007; 8(6): 449 - 456.
[Abstract] [Full Text] [PDF]

Home page
 Fam PractHome page
T Fahey, S Jeyaseelan, C McCowan, E Carr, B. Goudie, S. Pringle, P. Donnan, F. Sullivan, and A. Struthers
Diagnosis of left ventricular systolic dysfunction (LVSD): development and validation of a clinical prediction rule in primary care
Fam. Pract., December 1, 2007; 24(6): 628 - 635.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. E. Shoaf, Z. Wang, P. Bricmont, and S. Mallikaarjun
Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single-Dose Studies in Healthy Subjects
J. Clin. Pharmacol., December 1, 2007; 47(12): 1498 - 1507.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. Duckelmann, F. Mittermayer, D. G. Haider, J. Altenberger, J. Eichinger, and M. Wolzt
Asymmetric Dimethylarginine Enhances Cardiovascular Risk Prediction in Patients With Chronic Heart Failure
Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2037 - 2042.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
T. Breidthardt, M. Christ, M. Matti, D. Schrafl, K. Laule, M. Noveanu, T. Boldanova, T. Klima, W. Hochholzer, A. P Perruchoud, et al.
QRS and QTc interval prolongation in the prediction of long-term mortality of patients with acute destabilised heart failure
Heart, September 1, 2007; 93(9): 1093 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 ptjournalHome page
A. R. Lindquist, C. L Prado, R. M. Barros, R. Mattioli, P. H L. da Costa, and T. F Salvini
Gait Training Combining Partial Body-Weight Support, a Treadmill, and Functional Electrical Stimulation: Effects on Poststroke Gait
Physical Therapy, September 1, 2007; 87(9): 1144 - 1154.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. Breidthardt, K. Laule, A.-H. Strohmeyer, C. Schindler, S. Meier, M. Fischer, A. Scholer, M. Noveanu, M. Christ, A. P. Perruchoud, et al.
Medical and Economic Long-term Effects of B-Type Natriuretic Peptide Testing in Patients with Acute Dyspnea
Clin. Chem., August 1, 2007; 53(8): 1415 - 1422.
[Abstract] [Full Text] [PDF]

Home page
 Heart